This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Brookdale Senior Living (BKD) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Company News for May 2, 2025
by Zacks Equity Research
Companies In The News Are: CVS, LLY, CAH, ICE.
CAH Q3 Earnings Beat Estimates, '25 EPS View Raised, Stock Gains
by Zacks Equity Research
Cardinal Health's third-quarter fiscal 2025 results benefit from solid Medical and Other segment revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.
Cardinal (CAH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Cardinal (CAH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Cardinal Health (CAH) Beats Q3 Earnings Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 9.30% and 0.27%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Conmed (CNMD) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 17.28% and 2.42%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK
by Harshit Gupta
The medical device industry is growing fast in 2025, but faces supply and trade issues. Major companies to report earnings on May 1, stay tuned!
Can Sustained Product Demand Drive CAH Stock Before Q3 Earnings?
by Zacks Equity Research
The continued solid uptake of Cardinal Health's products is expected to have driven fiscal third-quarter revenues despite an uncertain macroeconomic environment.
Can Sustained Product Demand Drive BDX Stock Before Q2 Earnings?
by Zacks Equity Research
The continued solid uptake of BD's products is expected to have driven fiscal second-quarter revenues despite transitory market dynamics.
Henry Schein (HSIC) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardinal (CAH) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Evaluate the expected performance of Cardinal (CAH) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely?
by Zacks Equity Research
RVTY's first-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.
Cardinal Health (CAH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardinal Health (CAH) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
Cardinal Health (CAH) closed the most recent trading day at $133.69, moving +1.92% from the previous trading session.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Will Segmental Performance Drive West Pharmaceutical's Q1 Earnings?
by Zacks Equity Research
West Pharmaceutical Services' first-quarter results are likely to reflect growth amid pharma stabilization, biologics rebound & contract manufacturing gains.
Danaher Gears Up to Post Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
DHR's first-quarter earnings are likely to have been aided by strength in the Biotechnology segment. However, weakness in the Diagnostics and Life Sciences segments are expected to have hurt.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Cardinal Health (CAH) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Cardinal Health (CAH) closed the most recent trading day at $134.36, moving +0.08% from the previous trading session.
4 Stocks to Watch as Dental Supplies Recovers Amid Tariff Headwind
by Indrajit Bandyopadhyay
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These are CAH, MMSI, XRAY and CNMD.
Here's Why Cardinal Health (CAH) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DGX Stock Gains Following the Launch of New AD-Detect Blood Test
by Zacks Equity Research
Quest Diagnostics introduces AD-Detect Abeta, a new laboratory blood test, to detect Alzheimer's disease without any PET imaging and cerebral spinal fluid testing.
Cardinal Health (CAH) Stock Moves -1.2%: What You Should Know
by Zacks Equity Research
The latest trading day saw Cardinal Health (CAH) settling at $128.88, representing a -1.2% change from its previous close.
Align Technology (ALGN) Moves 14.4% Higher: Will This Strength Last?
by Zacks Equity Research
Align Technology (ALGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.